Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 Biogen Idec | Contract Pharma

What are you searching for?

Sign in
Breaking News, Financial News

Biogen Idec

Tysabri, Avonex revenues continue to climb

Author Image

By: Tim Wright

Editor-in-Chief, Contract Pharma

Biogen Idec 4Q10

4Q10 Revenues: $1.2 billion (+8%)

4Q10 Earnings: $272 million (-11%)

FY Revenues: $4.7 billion (+8%)

FY Earnings: $899 million (-8%)

Comments: Avonex sales rose 8% for the year to $2.5 billion and 10% for 4Q10 to $654 million. Tysabri revenues rose 16% for FY to $900 million and 12% to $242 million in 4Q10. Tysabri sales were split nearly 50/50 between U.S. and non-U.S. markets. Rituxan revenues dropped 2% to $1.1 billion for the year, due to expiration of royalties on non-U.S. sales

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters